What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Kenneth J. O'Byrne focuses on Lung cancer, Internal medicine, Oncology, Pathology and Surgery.
His Lung cancer research includes themes of Cancer research, Angiogenesis, Carcinoma and Hazard ratio.
His biological study deals with issues like Gastroenterology, which deal with fields such as Neutropenia and Mucositis.
His work carried out in the field of Oncology brings together such families of science as Disease, Evidence-based medicine, Docetaxel, Nivolumab and Ipilimumab.
Kenneth J. O'Byrne has researched Pathology in several fields, including Respiratory disease, Metastasis and Adenocarcinoma.
His work in the fields of Surgery, such as Phases of clinical research and Performance status, overlaps with other areas such as Multicenter trial.
His most cited work include:
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer (2444 citations)
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations (2003 citations)
- Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group (1305 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Lung cancer, Oncology, Cancer research and Cancer.
His studies deal with areas such as Gastroenterology and Surgery as well as Internal medicine.
His Lung cancer research is multidisciplinary, relying on both Carcinoma, Epidermal growth factor receptor and Adenocarcinoma.
His research in Oncology tackles topics such as Nivolumab which are related to areas like Ipilimumab.
Kenneth J. O'Byrne studied Cancer research and Cisplatin that intersect with Gemcitabine.
His Immunology research extends to Cancer, which is thematically connected.
He most often published in these fields:
- Internal medicine (48.31%)
- Lung cancer (47.42%)
- Oncology (40.18%)
What were the highlights of his more recent work (between 2017-2021)?
- Lung cancer (47.42%)
- Cancer research (40.77%)
- Internal medicine (48.31%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Lung cancer, Cancer research, Internal medicine, Oncology and Cancer.
His Lung cancer study combines topics from a wide range of disciplines, such as Liquid biopsy, Epidermal growth factor receptor, Chemotherapy and Circulating tumor cell.
The Cancer research study combines topics in areas such as Cell, Cisplatin, Cancer stem cell, non-small cell lung cancer and Biopsy.
In his work, Durvalumab is strongly intertwined with Mesothelioma, which is a subfield of Internal medicine.
In Oncology, Kenneth J. O'Byrne works on issues like Immunotherapy, which are connected to Tumor microenvironment.
Kenneth J. O'Byrne has included themes like Viability assay, Malignancy and Genome instability in his Cancer study.
Between 2017 and 2021, his most popular works were:
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden (1302 citations)
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (499 citations)
- Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi (242 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Kenneth J. O'Byrne mainly focuses on Lung cancer, Internal medicine, Oncology, Cancer research and Circulating tumor cell.
Kenneth J. O'Byrne interconnects Liquid biopsy, Chemotherapy and Epidermal growth factor receptor in the investigation of issues within Lung cancer.
Many of his studies involve connections with topics such as Mesothelioma and Internal medicine.
His biological study spans a wide range of topics, including Cancer, Clinical trial, Phases of clinical research, Nivolumab and Ipilimumab.
His research in Clinical trial intersects with topics in Carcinoma and Docetaxel.
His research integrates issues of DNA, DNA damage, DNA repair, Anaplastic lymphoma kinase and Biopsy in his study of Cancer research.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
